SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
SEC Accession No. 0001213900-21-005980
Filing Date
2021-02-02
Accepted
2021-02-02 08:30:38
Documents
4
Effectiveness Date
2021-02-02

Document Format Files

Seq Description Document Type Size
1 ea134192-posex_nlspharma.htm POS EX 94711
2 OPINION OF WENGER & VIELI AG, SWISS COUNSEL TO NLS PHARMACEUTICS LTD ea134192ex5-1_nlspharma.htm EX-5.1 55578
3 GRAPHIC ex5-1_001.jpg GRAPHIC 12407
4 GRAPHIC ex5-1_002.jpg GRAPHIC 24666
  Complete submission text file 0001213900-21-005980.txt   202600
Mailing Address ALTER POSTPLATZ 2 STANS V8 CH-6370
Business Address ALTER POSTPLATZ 2 STANS V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: POS EX | Act: 33 | File No.: 333-236797 | Film No.: 21579121
SIC: 2834 Pharmaceutical Preparations